-
Novartis Pharmaceuticals Corporation et al v. Actavis Inc. et al DC CAFC
- 1:13-cv-00371
- D. Del.
- Judge: Richard G. Andrews
- Filed: 03/07/2013
- Closed: 08/04/2014
- Latest Docket Entry: 06/30/2015
- PACER
5
Plaintiffs
4
Defendants
1
Accused
Product
2
Patents-in-Suit
516
Days in
Litigation
-
Novartis Pharmaceuticals Corporation et al v. Actavis Inc. et al DC CAFC
- 1:13-cv-00371
- D. Del.
- Judge: Richard G. Andrews
- Filed: 03/07/2013
- Closed: 08/04/2014
- Latest Docket Entry: 06/30/2015
- PACER
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 3 |
A pharmaceutical composition according to claim 1 wherein the anti-oxidant is tocopherol, esters thereof, ascorbic acid, butylhydroxytoluene, butylhydroxyanisole or propyl gallate.
|
Valid (103)
Entry 24 |
| 7 |
A transdermal device comprising a pharmaceutical composition as defined in claim 1, wherein the pharmaceutical composition is supported by a substrate.
|
Valid (103)
Entry 24 |
| 13 |
The transdermal device of claim 1, wherein the antioxidant is tocopherol, esters thereof, ascorbic acid, butylhydroxytoluene, butylhydroxyanisole, or propyl gallate.
|
Valid (103)
Entry 24 |
| 16 |
A method according to claim 15, wherein the anti-oxidant is tocopherol, esters thereof, ascorbic acid, butylhydroxytoluene, butylhydroxyanisole or propyl gallate.
|
Valid (103)
Entry 24 |
| 18 |
The method of claim 15, wherein the anti-oxidant is present in an amount of from about 0.01 to about 0.5% by weight based on the weight of the composition.
|
Valid (103)
Entry 24 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 2 |
The composition according to claim <HIL><BOLD>1</BOLD></HIL> wherein the antioxidant is selected from the group consisting of tocopherol, esters of tocopherol, ascorbic acid, esters of ascorbic acid, butylhydroxytoluene, butylhydroxyanisole, propyl
view more
|
Valid (103)
Entry 24 |
| 7 |
A transdermal device comprising a pharmaceutical composition comprising 1 to 40 weight percent of (S)-N-ethyl-3-[(1-dimethylamino)ethyl]-N-methylphenyl carbarnate in the form of a free base or acid addition salt, 0.01 to 0.5 weight percent of an
view more
|
Valid (103)
Entry 24 |
-
Infringement
Actavis Incorporated
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic 13.3 mg/24 hr dosage strength rivastigmine transdermal system pursuant to ANDA No. 202119Generic 4.6 mg/24 hr, 9.5 mg/24 hr dosage strength rivastigmine transdermal system pursuant to ANDA No. 202119 | US 6,316,023 B1 |
2, 7
|
Infringement
Entry 24
|
| Generic 13.3 mg/24 hr dosage strength rivastigmine transdermal system pursuant to ANDA No. 202119Generic 4.6 mg/24 hr, 9.5 mg/24 hr dosage strength rivastigmine transdermal system pursuant to ANDA No. 202119 | US 6,335,031 B1 |
3, 7, 13, 16, 18
|
Infringement
Entry 24
|
Watson Laboratories, Inc. (Connecticut)
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic 13.3 mg/24 hr dosage strength rivastigmine transdermal system pursuant to ANDA No. 202119Generic 4.6 mg/24 hr, 9.5 mg/24 hr dosage strength rivastigmine transdermal system pursuant to ANDA No. 202119 | US 6,316,023 B1 |
2, 7
|
Infringement
Entry 24
|
| Generic 13.3 mg/24 hr dosage strength rivastigmine transdermal system pursuant to ANDA No. 202119Generic 4.6 mg/24 hr, 9.5 mg/24 hr dosage strength rivastigmine transdermal system pursuant to ANDA No. 202119 | US 6,335,031 B1 |
3, 7, 13, 16, 18
|
Infringement
Entry 24
|
Watson Pharma, Inc.
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic 13.3 mg/24 hr dosage strength rivastigmine transdermal system pursuant to ANDA No. 202119Generic 4.6 mg/24 hr, 9.5 mg/24 hr dosage strength rivastigmine transdermal system pursuant to ANDA No. 202119 | US 6,316,023 B1 |
2, 7
|
Infringement
Entry 24
|
| Generic 13.3 mg/24 hr dosage strength rivastigmine transdermal system pursuant to ANDA No. 202119Generic 4.6 mg/24 hr, 9.5 mg/24 hr dosage strength rivastigmine transdermal system pursuant to ANDA No. 202119 | US 6,335,031 B1 |
3, 7, 13, 16, 18
|
Infringement
Entry 24
|